LifeMD (NASDAQ:LFMD) Stock Rating Lowered by Wall Street Zen

LifeMD (NASDAQ:LFMD) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other research firms also recently weighed in on LFMD. UBS Group reissued a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of LifeMD in a research note on Tuesday, May 26th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of LifeMD in a report on Monday, May 4th. Finally, Weiss Ratings upgraded shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.14.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $4.15 on Friday. LifeMD has a 12 month low of $2.56 and a 12 month high of $12.72. The firm has a market capitalization of $200.69 million, a P/E ratio of 83.02 and a beta of 1.99. The company’s fifty day moving average price is $4.55 and its 200 day moving average price is $3.97.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). The company had revenue of $50.16 million during the quarter, compared to analyst estimates of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. On average, sell-side analysts anticipate that LifeMD will post -0.37 EPS for the current year.

Institutional Investors Weigh In On LifeMD

A number of institutional investors have recently added to or reduced their stakes in LFMD. Tower Research Capital LLC TRC raised its stake in shares of LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after buying an additional 2,452 shares in the last quarter. Quarry LP purchased a new stake in shares of LifeMD in the third quarter valued at approximately $52,000. Legal & General Group Plc grew its holdings in LifeMD by 187.4% during the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after acquiring an additional 6,614 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in LifeMD during the fourth quarter worth $36,000. Finally, Hudson Bay Capital Management LP purchased a new position in LifeMD in the second quarter worth $153,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.